Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01713855 · ClinicalTrials.gov registry record · NA
Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura
A NA study of Immune Thrombocytopenic Purpura and Idiopathic Thrombocytopenic Purpura, sponsored by Neufeld, Ellis J, MD, PhD.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 3
- Study locations
NCT01713855 is a NA study of Immune Thrombocytopenic Purpura and Idiopathic Thrombocytopenic Purpura that has completed, run by Neufeld, Ellis J, MD, PhD. The registered enrollment target is 10 participants, below the 132-participant average among 3 other Immune Thrombocytopenic Purpura trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01713855, a NA study of Immune Thrombocytopenic Purpura and Idiopathic Thrombocytopenic Purpura, has completed, sponsored by Neufeld, Ellis J, MD, PhD.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine how children with a history of severe, chronic Idiopathic Thrombocytopenic Purpura (ITP) who were treated with rituximab might respond to vaccines. Eligible patients are previously or currently enrolled in a study entitled "Open Label, Phase I/II Trial of Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura in Children and Adolescents" and have decided to obtain an inactivated influenza vaccination. These patients will be invited to provide one blood sample prior to vaccination and a second sample following vaccination to quantify immune response to vaccination.
Conditions Studied
Interventions
- BIOLOGICAL Inactivated Trivalent Influenza vaccine
Study Locations (3)
California
- University of California, Los Angeles - Los Angeles
Georgia
- Emory University School of Medicine - Atlanta
Massachusetts
- Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2004-10 |
| Est. Completion | 2006-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01713855
The ClinicalTrials.gov registry entry for NCT01713855 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 132-participant average among 3 other Immune Thrombocytopenic Purpura trials with a reported enrollment target (92% lower). The listed sponsor is Neufeld, Ellis J, MD, PhD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Immune Thrombocytopenic Purpura appearing as the primary indexed condition, and to 1 intervention - of which Inactivated Trivalent Influenza vaccine is the first listed.
NCT01713855 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Georgia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01713855 about?
NCT01713855 is a clinical study titled "Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura". The purpose of this study is to determine how children with a history of severe, chronic Idiopathic Thrombocytopenic Purpura (ITP) who were treated with rituximab might respond to vaccines. Eligible patients are previously or currently enrolled in a study entitled "Open Label, Phase I/II Trial of Ri...
What is the current status of trial NCT01713855?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2004-10. Estimated completion is 2006-03.
What conditions does trial NCT01713855 study?
This clinical trial studies the following conditions: Immune Thrombocytopenic Purpura, Idiopathic Thrombocytopenic Purpura.
What interventions are being tested in trial NCT01713855?
The interventions under investigation include: Inactivated Trivalent Influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01713855?
This trial is sponsored by Neufeld, Ellis J, MD, PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01713855 being conducted?
This trial has 3 study locations across California, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Thrombocytopenic Purpura
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
COMPLETED · Phase 3
-
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
COMPLETED · Phase 3
-
An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers
COMPLETED
Explore more on PlainTrial
Immune Thrombocytopenic Purpura
All registered trials for this condition
Idiopathic Thrombocytopenic Purpura
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.